Drug Profile
Research programme: HIV integrase inhibitors - Novita Healthcare
Alternative Names: AVX 15567Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Avexa
- Developer Novita Healthcare
- Class Small molecules
- Mechanism of Action HIV integrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-infections in Australia (PO)
- 17 Apr 2014 Preclinical development is ongoing in Australia
- 27 Apr 2012 Preclinical development is ongoing in Australia